Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 87

Similar articles for PubMed (Select 11175785)

1.

A candidate prostate cancer susceptibility gene at chromosome 17p.

Tavtigian SV, Simard J, Teng DH, Abtin V, Baumgard M, Beck A, Camp NJ, Carillo AR, Chen Y, Dayananth P, Desrochers M, Dumont M, Farnham JM, Frank D, Frye C, Ghaffari S, Gupte JS, Hu R, Iliev D, Janecki T, Kort EN, Laity KE, Leavitt A, Leblanc G, McArthur-Morrison J, Pederson A, Penn B, Peterson KT, Reid JE, Richards S, Schroeder M, Smith R, Snyder SC, Swedlund B, Swensen J, Thomas A, Tranchant M, Woodland AM, Labrie F, Skolnick MH, Neuhausen S, Rommens J, Cannon-Albright LA.

Nat Genet. 2001 Feb;27(2):172-80.

PMID:
11175785
2.

Structure of primate and rodent orthologs of the prostate cancer susceptibility gene ELAC2.

Dumont M, Frank D, Moisan AM, Tranchant M, Soucy P, Breton R, Labrie F, Tavtigian SV, Simard J.

Biochim Biophys Acta. 2004 Sep 17;1679(3):230-47.

PMID:
15358515
3.

Evaluation of linkage and association of HPC2/ELAC2 in patients with familial or sporadic prostate cancer.

Xu J, Zheng SL, Carpten JD, Nupponen NN, Robbins CM, Mestre J, Moses TY, Faith DA, Kelly BD, Isaacs SD, Wiley KE, Ewing CM, Bujnovszky P, Chang B, Bailey-Wilson J, Bleecker ER, Walsh PC, Trent JM, Meyers DA, Isaacs WB.

Am J Hum Genet. 2001 Apr;68(4):901-11. Epub 2001 Mar 14.

4.

Genome-wide scan for prostate cancer susceptibility genes using families from the University of Michigan prostate cancer genetics project finds evidence for linkage on chromosome 17 near BRCA1.

Lange EM, Gillanders EM, Davis CC, Brown WM, Campbell JK, Jones M, Gildea D, Riedesel E, Albertus J, Freas-Lutz D, Markey C, Giri V, Dimmer JB, Montie JE, Trent JM, Cooney KA.

Prostate. 2003 Dec 1;57(4):326-34.

PMID:
14601029
5.

Linkage and association studies of prostate cancer susceptibility: evidence for linkage at 8p22-23.

Xu J, Zheng SL, Hawkins GA, Faith DA, Kelly B, Isaacs SD, Wiley KE, Chang B, Ewing CM, Bujnovszky P, Carpten JD, Bleecker ER, Walsh PC, Trent JM, Meyers DA, Isaacs WB.

Am J Hum Genet. 2001 Aug;69(2):341-50. Epub 2001 Jul 6.

6.

Podocalyxin variants and risk of prostate cancer and tumor aggressiveness.

Casey G, Neville PJ, Liu X, Plummer SJ, Cicek MS, Krumroy LM, Curran AP, McGreevy MR, Catalona WJ, Klein EA, Witte JS.

Hum Mol Genet. 2006 Mar 1;15(5):735-41. Epub 2006 Jan 24.

7.
8.

Truncating BRCA1 mutations are uncommon in a cohort of hereditary prostate cancer families with evidence of linkage to 17q markers.

Zuhlke KA, Madeoy JJ, Beebe-Dimmer J, White KA, Griffin A, Lange EM, Gruber SB, Ostrander EA, Cooney KA.

Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):5975-80.

9.

Genome-wide linkage analysis for aggressive prostate cancer in Utah high-risk pedigrees.

Christensen GB, Camp NJ, Farnham JM, Cannon-Albright LA.

Prostate. 2007 May 1;67(6):605-13.

PMID:
17299800
10.

Role of HPC2/ELAC2 in hereditary prostate cancer.

Wang L, McDonnell SK, Elkins DA, Slager SL, Christensen E, Marks AF, Cunningham JM, Peterson BJ, Jacobsen SJ, Cerhan JR, Blute ML, Schaid DJ, Thibodeau SN.

Cancer Res. 2001 Sep 1;61(17):6494-9.

11.

Germ-line mutation of NKX3.1 cosegregates with hereditary prostate cancer and alters the homeodomain structure and function.

Zheng SL, Ju JH, Chang BL, Ortner E, Sun J, Isaacs SD, Sun J, Wiley KE, Liu W, Zemedkun M, Walsh PC, Ferretti J, Gruschus J, Isaacs WB, Gelmann EP, Xu J.

Cancer Res. 2006 Jan 1;66(1):69-77.

12.

Polymorphisms in the prostate cancer susceptibility gene HPC2/ELAC2 in multiplex families and healthy controls.

Suarez BK, Gerhard DS, Lin J, Haberer B, Nguyen L, Kesterson NK, Catalona WJ.

Cancer Res. 2001 Jul 1;61(13):4982-4.

13.

Combined genome-wide scan for prostate cancer susceptibility genes.

Gillanders EM, Xu J, Chang BL, Lange EM, Wiklund F, Bailey-Wilson JE, Baffoe-Bonnie A, Jones M, Gildea D, Riedesel E, Albertus J, Isaacs SD, Wiley KE, Mohai CE, Matikainen MP, Tammela TL, Zheng SL, Brown WM, Rökman A, Carpten JD, Meyers DA, Walsh PC, Schleutker J, Gronberg H, Cooney KA, Isaacs WB, Trent JM.

J Natl Cancer Inst. 2004 Aug 18;96(16):1240-7.

14.

Perspective: prostate cancer susceptibility genes.

Simard J, Dumont M, Soucy P, Labrie F.

Endocrinology. 2002 Jun;143(6):2029-40. Review.

PMID:
12021166
15.

ELAC2/HPC2 involvement in hereditary and sporadic prostate cancer.

Rökman A, Ikonen T, Mononen N, Autio V, Matikainen MP, Koivisto PA, Tammela TL, Kallioniemi OP, Schleutker J.

Cancer Res. 2001 Aug 15;61(16):6038-41.

16.

Confirmation of the HPCX prostate cancer predisposition locus in large Utah prostate cancer pedigrees.

Farnham JM, Camp NJ, Swensen J, Tavtigian SV, Albright LA.

Hum Genet. 2005 Feb;116(3):179-85. Epub 2004 Dec 8.

PMID:
15592687
17.

The product of the candidate prostate cancer susceptibility gene ELAC2 interacts with the gamma-tubulin complex.

Korver W, Guevara C, Chen Y, Neuteboom S, Bookstein R, Tavtigian S, Lees E.

Int J Cancer. 2003 Apr 10;104(3):283-8.

PMID:
12569551
18.

Genomic search for prostate cancer predisposition loci in Utah pedigrees.

Camp NJ, Farnham JM, Cannon Albright LA.

Prostate. 2005 Dec 1;65(4):365-74.

PMID:
16037989
19.

Prostate cancer susceptibility genes: lessons learned and challenges posed.

Simard J, Dumont M, Labuda D, Sinnett D, Meloche C, El-Alfy M, Berger L, Lees E, Labrie F, Tavtigian SV.

Endocr Relat Cancer. 2003 Jun;10(2):225-59. Review.

20.

Genome linkage screen for prostate cancer susceptibility loci: results from the Mayo Clinic Familial Prostate Cancer Study.

Cunningham JM, McDonnell SK, Marks A, Hebbring S, Anderson SA, Peterson BJ, Slager S, French A, Blute ML, Schaid DJ, Thibodeau SN; Mayo Clinic, Rochester, Minnesota.

Prostate. 2003 Dec 1;57(4):335-46.

PMID:
14601030
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk